SS-31 Interactions: Alcohol, Caffeine, Food and Compound Combinations

Questions about how SS-31 (Szeto-Schiller 31, elamipretide) behaves alongside alcohol, caffeine, food, fasting windows, or other supplements and drugs are common. The honest starting point is that the published SS-31 literature is almost entirely mechanistic, preclinical and disease-model work. In the verified body of papers summarised here, no study examined SS-31 co-administered with ethanol, caffeine, or a meal. What the literature does describe in detail is a different kind of interaction: how the peptide interacts with membranes, with a specific protein target, and with the wider mitochondrial proteome. This page reports those findings and, where no interaction study exists, states that plainly and describes the mechanistic reasoning researchers apply — labeled as reasoning, not as evidence.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about medicines, supplements or interactions. A broader overview of the compound sits on PeptideU's SS-31 hub at /learn/ss-31/.

What "Interaction" Means in the SS-31 Literature

In pharmacology, "interaction" usually means one substance changing another's absorption, distribution, metabolism, excretion or effect. In the SS-31 papers, the word almost always refers to molecular binding instead. Researchers reported that SS-31 bound lipid bilayers and modulated membrane surface electrostatics, describing this as a key component of its mechanism of action (PMID 32273339). A separate group used a proteome-scale approach to map the mitochondrial protein interaction landscape of SS-31, identifying mitochondrial proteins that associated with the peptide (PMID 32554501).

A genome-wide CRISPR screen took the target question further and identified phospholipid scramblase 3 as the biological target of the mitoprotective compound SS-31 (PMID 38530359). Structure-focused work on mitochondria-targeted tetrapeptide compounds examined structure–activity relationships across related sequences, showing that the peptide's activity depended on its specific chemistry rather than being a generic property of cationic tetrapeptides (PMID 35913044). Taken together, these mechanism papers describe a molecule whose primary reported interactions are with lipids and proteins inside mitochondria (PMID 32273339, PMID 38530359).

That distinction matters for every question below. A molecule characterised through membrane binding and protein-target screens has not, by that fact alone, been characterised for drug–drug or drug–diet interactions. Those are separate experiments, and in the verified set they were not performed.

SS-31 and Alcohol: No Interaction Study Identified

No paper in the verified set examined SS-31 together with ethanol, in animals, cells or humans. There is no reported finding on how alcohol intake alters SS-31 distribution, and no reported finding on how SS-31 alters alcohol metabolism or alcohol-related tissue changes.

Mechanistic reasoning (researchers' framework, not a study finding): because researchers described SS-31 as acting at mitochondrial membranes through lipid binding and surface electrostatics (PMID 32273339), and because ethanol is itself metabolised in ways that influence mitochondrial redox handling, investigators discussing overlap in this space reason about shared mitochondrial territory rather than about a documented pharmacokinetic interaction. The same reasoning appears in reviews of mitochondrial approaches to neuroprotection, which framed mitochondria-targeted agents as interventions acting on bioenergetics and oxidative stress pathways (PMID 19076459). Overlapping biology is a hypothesis-generating observation; it is not an interaction result, and no verified paper has tested it.

SS-31 and Caffeine: No Interaction Study Identified

Likewise, no verified study combined SS-31 with caffeine or other methylxanthines, and none measured caffeine's effect on peptide exposure or vice versa. Nothing in the citation set supports any statement about timing, additive stimulation, or blunted effects.

Mechanistic reasoning (labeled as such): caffeine is widely discussed in terms of adenosine receptor signalling and downstream cyclic-AMP effects, while the SS-31 papers describe a molecule whose identified target was phospholipid scramblase 3 and whose reported activity centred on mitochondrial membranes (PMID 38530359, PMID 32273339). Researchers working on this compound have therefore had no obvious shared-target rationale to test, which is one reason such a study does not appear in the literature. That absence should be read as untested, not as reassurance.

Food, Fasting and Administration Context

The verified literature does not contain a food-effect study for SS-31 — that is, no experiment compared the peptide's behaviour in fed versus fasted conditions, and none examined fasting windows, meal composition or macronutrient timing. The studies available were designed around cells, isolated mitochondria, tissue models and animal disease models rather than around oral dosing pharmacokinetics.

What researchers did report is biology that is itself metabolically sensitive. A 2019 investigation in the context of type 2 diabetes reported that the mitochondrial antioxidant SS-31 modulated oxidative stress, endoplasmic reticulum stress and autophagy (PMID 31466264). Because nutrient availability is one of the main physiological inputs to autophagy and to endoplasmic reticulum stress, researchers reason — again, as reasoning rather than as a demonstrated interaction — that feeding state could plausibly modify the same readouts the study measured (PMID 31466264). No experiment in the verified set has isolated that variable.

Compound Combinations That Studies Actually Examined

A small number of papers did combine SS-31-type mitoprotection with other agents or materials, but these were engineered delivery systems, not conventional co-administration studies.

Nanoplatform and biomaterial combinations

Researchers described a duplex-responsive nanoplatform with cascade targeting built for atherosclerosis photoacoustic diagnosis and multichannel combination therapy, in which multiple therapeutic channels were packaged into a single construct (PMID 36828777). A later materials study reported peptide coacervate–Prussian blue hybrid supraparticle-tailored scaffolds aimed at diabetic heart valve regeneration through multiplex oxidative stress regulation, again combining a peptide component with an inorganic antioxidant material (PMID 41145022). These reports describe combinations engineered at the formulation level; they do not describe what happens when separate substances are consumed independently.

Pathway-level combinations

Other work situated the peptide alongside specific signalling pathways. A 2025 study reported that Szeto-Schiller 31 eased acute lung injury in neonatal mice with acute respiratory distress syndrome by mediating TXNIP expression and NLRP3 inflammasome activation (PMID 40800174). Work on allergic airway inflammation reported that YTHDF1-mediated mitochondrial dysfunction interacted with β-catenin/TCF4 signalling (PMID 40633209). A 2026 chemical-biology paper reported that the therapeutic peptide SS-31 modulated membrane binding and aggregation of α-synuclein and restored impaired mitochondrial function (PMID 42219795). These are interactions with endogenous proteins and pathways — a different category from consumer-style combination questions.

Commonly Asked Combinations and What the Verified Literature Shows

Interaction-Related Adverse Events: What Studies Report

The verified papers were not designed as combination-toxicity studies, and none reported adverse events arising from pairing SS-31 with alcohol, caffeine, food or another named compound. Reported outcomes were instead framed around the intended biology: easing of acute lung injury in neonatal mice with acute respiratory distress syndrome through TXNIP and NLRP3 inflammasome mechanisms (PMID 40800174), and modulation of oxidative stress, endoplasmic reticulum stress and autophagy in the type 2 diabetes setting (PMID 31466264).

One nuance researchers raised is that mechanism itself can cut both ways. Because the peptide was reported to alter membrane surface electrostatics (PMID 32273339) and because a specific membrane protein was identified as its target (PMID 38530359), the biological consequences depend on context — cell type, mitochondrial state, and concentration. Structure–activity work reinforced that small chemical changes altered activity across mitochondria-targeted tetrapeptides (PMID 35913044). None of that translates into a documented interaction risk profile, because the experiments needed to produce one have not been published in this set.

Why the Interaction Literature Is Thin

• Stage of research. The verified work is dominated by mechanism and disease-model studies, such as the mitochondrial protein interaction landscape mapping (PMID 32554501) and the CRISPR target screen (PMID 38530359). Interaction studies typically follow later in development.
• Model systems. Cells, isolated mitochondria and rodent models were the usual settings, including the neonatal mouse lung injury work (PMID 40800174), and such designs rarely include dietary or recreational-substance variables.
• Formulation focus. Where combinations appeared, they were engineered constructs rather than separate agents taken together (PMID 36828777, PMID 41145022).
• Target novelty. Because a specific phospholipid-handling protein was only recently identified as the target (PMID 38530359), systematic interaction mapping against common drugs has not yet been reported in this citation set.

How to Read Interaction Claims About SS-31

Three questions help separate evidence from extrapolation. First, did a study administer both substances? In the verified set, for alcohol, caffeine and food, the answer is no. Second, if a mechanism is invoked, is it a reported mechanism? Membrane binding and electrostatic modulation were reported findings (PMID 32273339), as was the identification of a protein target (PMID 38530359). Third, does the claimed outcome exist anywhere in the cited paper's scope? Reported outcomes in this set include α-synuclein membrane binding and aggregation changes with restored mitochondrial function (PMID 42219795) and mitochondrial dysfunction linked to β-catenin/TCF4 signalling in allergic airway inflammation (PMID 40633209) — not interaction endpoints.

Elamipretide-class peptides remain research compounds in most jurisdictions, and materials supplied for laboratory use are labeled research-use-only. Regulatory status is a separate matter from interaction data: neither one substitutes for the other, and neither is legal or medical advice.

References

• The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action (The Journal of Biological Chemistry, 2020)
• Mitochondrial protein interaction landscape of SS-31 (Proceedings of the National Academy of Sciences of the United States of America, 2020)
• Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31 (Journal of the American Society of Nephrology, 2024)
• Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds (eLife, 2022)
• The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes (Journal of Clinical Medicine, 2019)
• Szeto-Schiller 31 eases acute lung injury in neonatal mice with acute respiratory distress syndrome by mediating TXNIP expression and NLRP3 inflammasome activation (Translational Pediatrics, 2025)
• YTHDF1-mediated mitochondrial dysfunction and allergic airway inflammation by interaction with β-catenin/TCF4 signaling (International Immunopharmacology, 2025)
• Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function (Chemical Biology & Drug Design, 2026)
• Duplex Responsive Nanoplatform with Cascade Targeting for Atherosclerosis Photoacoustic Diagnosis and Multichannel Combination Therapy (Advanced Materials, 2023)
• Peptide coacervate-Prussian blue hybrid supraparticle-tailored scaffolds for revitalizing diabetic heart valve regeneration via multiplex oxidative stress regulation (Biomaterials, 2026)
• Mitochondrial approaches for neuroprotection (Annals of the New York Academy of Sciences, 2008)